Breaking News
Get 40% Off 0
🔎 See NVDA's full ProTips for an instant risks or rewards Claim 40% OFF
Close

Amgen Inc (AMGN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
267.200 0.000    0.00%
16/02 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 265.200 / 268.600
  • Day's Range: 267.200 - 268.000
Type:  Equity
Market:  Austria
ISIN:  US0311621009 
Amgen 267.200 0.000 0.00%

AMGN Balance Sheet

 
Featured here, the Balance Sheet for Amgen Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 30332 48477 47380 44703
Cash and Short Term Investments 10944 34741 34248 31561
Cash - - - -
Cash & Equivalents 10944 34741 34248 31560
Short Term Investments - - - 1
Total Receivables, Net 7942 6145 5830 5736
Accounts Receivables - Trade, Net 7268 6145 5830 5736
Total Inventory 9518 5026 4978 5011
Prepaid Expenses 1647 - - -
Other Current Assets, Total 281 2565 2324 2395
Total Assets 97154 90534 90269 88720
Property/Plant/Equipment, Total - Net 6592 5563 5532 5460
Property/Plant/Equipment, Total - Gross 16400 15263 15032 14860
Accumulated Depreciation, Total -9808 -9700 -9500 -9400
Goodwill, Net 18629 15509 15531 15531
Intangibles, Net 32641 13150 14633 15393
Long Term Investments 4454 4275 4314 5368
Note Receivable - Long Term 674 - - -
Other Long Term Assets, Total 4506 3560 2879 2265
Other Assets, Total 1857 1446 1472 1671
Total Current Liabilities 18392 16954 17097 14215
Accounts Payable 1590 1358 1212 1320
Payable/Accrued - - - -
Accrued Expenses 12371 14114 13718 11929
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 1562 1428 2167 834
Other Current liabilities, Total 2869 54 - 132
Total Liabilities 90922 82878 83488 83372
Total Long Term Debt 63170 59040 59377 60761
Long Term Debt 63170 59040 59377 60761
Capital Lease Obligations - - - -
Deferred Income Tax 2354 - - -
Minority Interest - - - -
Other Liabilities, Total 3006 6884 7014 8396
Total Equity 6232 7656 6781 5348
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 33070 32753 32601 32535
Additional Paid-In Capital - - - -
Retained Earnings (Accumulated Deficit) - -24971 -25540 -26919
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total -289 -126 -280 -268
Total Liabilities & Shareholders' Equity 97154 90534 90269 88720
Total Common Shares Outstanding 535.4 535.1 534.9 534.3
Total Preferred Shares Outstanding - - - -
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AMGN Comments

Write your thoughts about Amgen Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email